Editor's Corner


Today I'm reporting live from BIO, the annual conference of the Biotechnology Industry Organization. The show is now fully underway this morning as 18,000 biotech players from around the globe arrive in Philadelphia. This is a chance for hundreds of biotech companies to tout their progress and discuss stem cell research, the growing alliance between biotech companies and big pharma, and what India and China mean for the future of drug development. FierceBiotech will put the spotlight on emerging private biotech companies in this evening's announcement of the Fierce 15, with the special issue coming out tomorrow for all readers. - John Carroll

Suggested Articles

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.

The top-line readout appears to justify the risk the partners took when they advanced the drug despite missing the primary endpoint in phase 2.